Janssen-Cilag Pharma GmbH

Clinical trials sponsored by Janssen-Cilag Pharma GmbH, explained in plain language.

Now part of Johnson & Johnson JNJ NYSE

A pharmaceutical company, part of the Janssen family, developing and marketing medicines.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Trials to join now! 1

Real-World study tracks how long patients stick with gut disease drug

Disease control Recruiting now

This study observes 35 adults with moderate-to-severe Crohn's disease or ulcerative colitis to see how long they continue taking guselkumab in everyday medical practice. Researchers will track treatment persistence and early symptom relief, like reduced bowel urgency. No experime…

Sponsor: Janssen-Cilag Pharma GmbH • Aim: Disease control

Last updated Aug 30, 2026 00:00 UTC

Janssen-Cilag Pharma GmbH

Real-World study tracks how long patients stick with gut disease drug